25I-NBOH
25I-NBOH
25I-NBOH, also known as 2C-I-NBOH, is a potent psychedelic compound that belongs to the N-benzylphenethylamine class. It is a derivative of the phenethylamine 2C-I and is closely related to the NBOMe series of compounds. 25I-NBOH is known for its strong binding affinity to the 5-HT2A receptor, which is believed to be responsible for its psychedelic effects.
Chemical Structure
25I-NBOH is chemically similar to 2C-I, with the addition of a 2-hydroxybenzyl group attached to the nitrogen atom of the phenethylamine backbone. This modification increases its potency and alters its pharmacological profile compared to its parent compound, 2C-I.
Pharmacology
The primary mechanism of action for 25I-NBOH is its agonistic activity at the 5-HT2A receptor, a subtype of the serotonin receptor that is implicated in the modulation of mood, perception, and cognition. The compound's high affinity for this receptor is thought to underlie its psychedelic effects, which can include altered visual and auditory perceptions, changes in thought patterns, and emotional experiences.
Effects
The effects of 25I-NBOH are similar to those of other psychedelics, such as LSD and psilocybin. Users may experience visual hallucinations, synesthesia, and a distorted sense of time. The intensity and duration of these effects can vary depending on the dose and individual sensitivity.
Safety and Toxicity
As with many research chemicals, the safety profile of 25I-NBOH is not well-established. There have been reports of adverse effects, including vasoconstriction, tachycardia, and hypertension, particularly at higher doses. Due to its potency and the potential for overdose, caution is advised when handling this compound.
Legal Status
The legal status of 25I-NBOH varies by country. In some jurisdictions, it is classified as a controlled substance, while in others, it may be legal or unregulated. It is important to be aware of the local laws regarding the possession and use of this compound.
Related Compounds
See Also
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
